Previous 10 | Next 10 |
Radnor, Pennsylvania--(Newsfile Corp. - August 24, 2023) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ: BTAI). The action charges BioXcel wi...
2023-08-15 18:26:32 ET More on BioXcel Therapeutics BioXcel's Struggles: From FDA Issues To Financial Instability BioXcel Therapeutics, Inc. ( BTAI ) Q2 2023 Earnings Call Transcript BioXcel: Data Integrity Concerns Muddy Regulatory Outlook (Rating Downgrade) ...
2023-08-15 17:43:59 ET Even though it's only Tuesday, BioXcel Therapeutics (NASDAQ: BTAI) is having a week to forget. After the biotech's share price tanked on Monday on the back of less-than-inspiring quarterly results and the announcement of significant job cuts, it was hammered a...
2023-08-15 09:51:56 ET Summary BioXcel Therapeutics faces marketability concerns, FDA issues, and credibility problems from inspections. Financial challenges include significant losses, debt, and a short cash runway. Given unresolved issues and weak financials, a "Strong Sell"...
2023-08-14 13:08:50 ET Gainers: Taysha Gene Therapies ( TSHA ) +129% . Hanryu Holdings ( HRYU ) +40% . Genius Group Limited ( GNS ) +38% . United States Steel Corporation ( X ) +32% . TMC the metals company ( TMC ) +25% . U P...
2023-08-14 12:01:06 ET BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market Intelligence . BioXcel published its second-quarter resu...
2023-08-14 10:48:10 ET BioXcel Therapeutics, Inc. (BTAI) Q2 2023 Earnings Conference Call August 14, 2023 08:00 AM ET Company Participants Vimal Mehta - Founder & CEO Richard Steinhart - SVP & CFO Matt Wiley - SVP & Chief Commercial Officer Robert...
2023-08-14 07:38:57 ET More on BioXcel BioXcel: Data Integrity Concerns Muddy Regulatory Outlook (Rating Downgrade) BioXcel Therapeutics: Serenity III Part 1 Didn't Meet Primary Endpoints, Part 2 Will BioXcel Therapeutics: Clinical Trial Milestones Drive Stock But Sl...
2023-08-14 07:05:04 ET BioXcel Therapeutics press release ( NASDAQ: BTAI ): Q2 GAAP EPS of -$1.83 misses by $0.11 . Revenue of $0.46M misses by $0.01M . Cash and cash equivalents totaled $127.5 million as of June 30, 2023. As noted above, the Company is underta...
B usiness to prioritize high- potential agitation market opportunities for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer’s disease Commercial reprioritization intended to reduce related expenses by 80% with focus on market access throu...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...